Leading a biotherapeutics discovery team with diverse expertise in: - protein engineering using structure guided design and combinatorial library selections- naïve antibody discovery campaigns (phage and mammalian display, hybridoma)- transient and stable cell mammalian protein expression and protein purification- biophysical protein characterization- in vitro functional immune cell assays (ADCC, T cell cytotoxicity)- in vivo study design (efficacy, PK, PD)Overseeing early discovery projects:- Multi-specific/bispecific immune cell retargeting antibodies- Cytokines/ligand/receptor Fc fusion proteins- Novel targets of tumor cell senescence

- Head of antibody technology and protein science group- Development of monoclonal and bispecific antibodies and cytokine fusion proteins- Antibody discovery using phage/yeast display technology and animal immunization - Antibody humanization and affinity maturation- Protein engineering and process development- Mammalian protein production - transient and stable cell line development- Member of research leadership team - strategic/goal/timeline/budget planning- IND core team member - Primary inventor of preclinical candidates: MM-201 and MM-401

- Group leader and inventor of proprietary antibody yeast display platform - Key contributor in the construction and panning of 200 billion member antibody phage library - Development of a novel M13KO7 strain for improved antibody display on phage

- Construction and screening of protease libraries on phage and yeast- Identified lead proteases with 50-fold improvement in catalytic activity and selectivity

- Construction and screening of peptide phage libraries - Discovery and characterization of inhibitory peptides of HGF/Met signaling